Furthermore, given the outstanding inhibition of tumor growth demonstrated by EZH2 inhibitors in combination with anti-PD-1 therapy, Tazemetostat has been approved as the most widely studied EZH2 inhibitor as a first-line treatment option for epithelioid sarcoma (112, 114). This evidence concerns the gene PDCD1 and neoplasm.